Ray Data

From a "Fool" article in June of this year:
----------------------------------------
Tapping a big market

The market for Rayaldee is conceivably massive. The drug addresses secondary hyperparathyroidism that's due to vitamin D insufficiency in patients diagnosed with stage 3 or stage 4 chronic kidney disease (CKD). There are an estimated 9 million Americans who could benefit from Rayaldee treatment.

When patients suffer from vitamin D insufficiency, excessive amounts of parathyroid hormone are secreted. If that hormone remains too high for too long, it can lead to calcium and phosphorous being released from bone. In addition to weakening bones, this situation can lead to the calcification of vascular tissue and renal tissue that can be life-threatening. Between 40% and 60% of stage 3 and stage 4 CKD patients are affected by this condition.

In trials, patients taking Rayaldee achieved at least 30% reductions in plasma intact parathyroid hormone versus placebo, and Vitamin D insufficiency was corrected in more than 80% of the patients. For comparison, less than 7% of people who received placebo saw their vitamin D insufficiency corrected.

In approving Rayaldee, the FDA gave a go ahead to the first FDA-approved therapy designed to address this condition. Currently, stage 3 and stage 4 CKD patients are treated with high-dose vitamin D supplements with arguable efficacy.
--------------------------------
If we got 10% of that 9 million as patients/customers, it would be a massive success,

C L